|
|
 Previous Article | Table of Contents | Next Article 
Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group
Fatih M. Uckun,
Harland N. Sather,
Paul S. Gaynon,
Diane C. Arthur,
Michael E. Trigg,
David G. Tubergen,
James Nachman,
Peter G. Steinherz,
Martha G. Sensel, and
Gregory H. Reaman
From the Children's Cancer Group ALL Biology Reference Laboratory and Hughes Institute, St Paul, MN; the Department of Preventive Medicine, University of Southern California, Los Angeles; the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD; the Department of Pediatric Hematology-Oncology, University of Wisconsin, Madison; the Department of Pediatric Hematology-Oncology, University of Iowa Hospital and Clinics, Iowa City; the Department of Pediatrics, M.D. Anderson Cancer Center, Houston, TX; the Department of Pediatric Hematology-Oncology, University of Chicago, Chicago, IL; the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY; the Department of Hematology-Oncology, Children's National Medical Center, and the George Washington University, Washington, DC; and the Group Operations Center of the Children's Cancer Group, Arcadia, CA.
Leukemic cells from a significant number of children with acute lymphoblastic leukemia (ALL) express protein antigens characteristic of both lymphoid and myeloid cells, yet the clinical significance of this immunophenotype has remained controversial. In the current study, we have determined relationships between myeloid antigen expression and treatment outcome in a large cohort of children with newly diagnosed ALL. A total of 1,557 children enrolled on risk-adjusted Children's Cancer Group studies were classified as myeloid antigen positive (My+) or myeloid antigen negative (My-) B-lineage ALL (BL) or T-lineage ALL (TL), according to expression of CD7, CD19, CD13, and CD33 antigens on the surface of their leukemic cells. My+ patients in both BL and TL groups were more likely than My- patients to have favorable presenting features. Induction therapy outcome was similar for My+ and My- patients in both the BL and TL categories. Importantly, 4-year event-free survival (EFS) was similar for My+ BL (77.0%, standard deviation [SD] = 4.0%) versus My- BL (75.9%, SD = 1.8%) and for My+ TL (72.7%, SD = 7.1%) versus My- TL (70.1%, SD = 5.7%). An overall relative hazard rate (RHR) of 0.89 (P = .49) was determined by a cross strata analysis for My+ versus My- patients. Moreover, similar EFS and RHR also were found when My+ and My- BL patients were compared according to National Cancer Institute risk classification. Thus, patients with My+ ALL have similar treatment outcomes as My- ALL patients. In contrast to previous studies, this result was independent of treatment risk category, demonstrating that myeloid antigen expression was not an adverse prognostic factor for childhood ALL.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 28-35
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. E. Rubnitz, M. Onciu, S. Pounds, S. Shurtleff, X. Cao, S. C. Raimondi, F. G. Behm, D. Campana, B. I. Razzouk, R. C. Ribeiro, et al.
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital
Blood,
May 21, 2009;
113(21):
5083 - 5089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vitale, A. Guarini, C. Ariola, M. Mancini, C. Mecucci, A. Cuneo, F. Pane, G. Saglio, G. Cimino, A. Tafuri, et al.
Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol
Blood,
January 15, 2006;
107(2):
473 - 479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed
Pediatric Acute Lymphoblastic Leukemia
Hematology,
January 1, 2003;
2003(1):
102 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Heerema, H. N. Sather, M. G. Sensel, M. K. Lee, R. J. Hutchinson, J. B. Nachman, G. H. Reaman, B. J. Lange, P. G. Steinherz, B. C. Bostrom, et al.
Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
November 15, 2000;
18(22):
3837 - 3844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Uckun, L. Stork, N. Seibel, M. Sarquis, C. Bedros, H. Sather, M. Sensel, G. H. Reaman, and P. S. Gaynon
Residual Bone Marrow Leukemic Progenitor Cell Burden after Induction Chemotherapy in Pediatric Patients with Acute Lymphoblastic Leukemia
Clin. Cancer Res.,
August 1, 2000;
6(8):
3123 - 3130.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Toyoda, A. Manabe, M. Tsuchida, R. Hanada, K. Ikuta, Y. Okimoto, A. Ohara, Y. Ohkawa, T. Mori, K. Ishimoto, et al.
Six Months of Maintenance Chemotherapy After Intensified Treatment for Acute Lymphoblastic Leukemia of Childhood
J. Clin. Oncol.,
April 7, 2000;
18(7):
1508 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, S. O’Brien, T. L. Smith, J. Cortes, F. J. Giles, M. Beran, S. Pierce, Y. Huh, M. Andreeff, C. Koller, et al.
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
J. Clin. Oncol.,
February 1, 2000;
18(3):
547 - 547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Heerema, J. B. Nachman, H. N. Sather, M. G. Sensel, M. K. Lee, R. Hutchinson, B. J. Lange, P. G. Steinherz, B. Bostrom, P. S. Gaynon, et al.
Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group
Blood,
December 15, 1999;
94(12):
4036 - 4045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sun, P. A. Goodman, C. M. Wood, M.-L. Crotty, M. Sensel, H. Sather, C. Navara, J. Nachman, P. G. Steinherz, P. S. Gaynon, et al.
Expression of Aberrantly Spliced Oncogenic Ikaros Isoforms in Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
December 1, 1999;
17(12):
3753 - 3766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Uckun, Y. Messinger, C.-L. Chen, K. O'Neill, D. E. Myers, F. Goldman, C. Hurvitz, J. T. Casper, and A. Levine
Treatment of Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia with an Apoptosis-inducing CD19-directed Tyrosine Kinase Inhibitor
Clin. Cancer Res.,
December 1, 1999;
5(12):
3906 - 3913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Uckun, P. S. Gaynon, D. O. Stram, M. G. Sensel, M. B. Sarquis, K. H. Lazarus, and M. Willoughby
Paucity of Leukemic Progenitor Cells in the Bone Marrow of Pediatric B-Lineage Acute Lymphoblastic Leukemia Patients with an Isolated Extramedullary First Relapse
Clin. Cancer Res.,
September 1, 1999;
5(9):
2415 - 2420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Felix and B. J. Lange
Leukemia in Infants
Oncologist,
June 1, 1999;
4(3):
225 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. Sun, N. Heerema, L. Crotty, X. Wu, C. Navara, A. Vassilev, M. Sensel, G. H. Reaman, and F. M. Uckun
Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia
PNAS,
January 19, 1999;
96(2):
680 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui and W. E. Evans
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
August 27, 1998;
339(9):
605 - 615.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Putti, R. Rondelli, M. G. Cocito, M. Arico, L. Sainati, V. Conter, C. Guglielmi, A. Cantu-Rajnoldi, R. Consolini, A. Pession, et al.
Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies
Blood,
August 1, 1998;
92(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Uckun, K. Herman-Hatten, M.-L. Crotty, M. G. Sensel, H. N. Sather, L. Tuel-Ahlgren, M. B. Sarquis, B. Bostrom, J. B. Nachman, P. G. Steinherz, et al.
Clinical Significance of MLL-AF4 Fusion Transcript Expression in the Absence of a Cytogenetically Detectable t(4;11)(q21;q23) Chromosomal Translocation
Blood,
August 1, 1998;
92(3):
810 - 821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Uckun, M. G. Sensel, L. Sun, P. G. Steinherz, M. E. Trigg, N. A. Heerema, H. N. Sather, G. H. Reaman, and P. S. Gaynon
Biology and Treatment of Childhood T-Lineage Acute Lymphoblastic Leukemia
Blood,
February 1, 1998;
91(3):
735 - 746.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Rubnitz and C.-H. Pui
Childhood Acute Lymphoblastic Leukemia
Oncologist,
December 1, 1997;
2(6):
374 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
